← Pipeline|Rimaratamab

Rimaratamab

NDA/BLA
CYB-9706
Source: Trial-derived·Trials: 1
Modality
Bispecific Ab
MOA
USP1i
Target
MDM2
Pathway
Checkpoint
Obesity
Development Pipeline
Preclinical
~Apr 2012
~Jul 2013
Phase 1
~Oct 2013
~Jan 2015
Phase 2
~Apr 2015
~Jul 2016
Phase 3
~Oct 2016
~Jan 2018
NDA/BLA
Apr 2018
Mar 2028
NDA/BLACurrent
NCT04326247
227 pts·Obesity
2018-042028-03·Terminated
227 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-172.0y awayPh3 Readout· Obesity
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-03-17 · 2.0y away
Obesity
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04326247NDA/BLAObesityTerminated227Safety
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-6079Eli LillyPhase 2MDM2PRMT5i
LLY-3251Eli LillyPhase 2MDM2BiTE
SNY-2934SanofiPhase 3KRASG12DUSP1i
GSK-7987GSKPhase 3MDM2PD-1i
AMG-2752AmgenPreclinicalMDM2WRNi
AMG-9052AmgenPhase 2/3CDK2USP1i
REG-3155RegeneronPhase 1/2MDM2PI3Ki
DatozumabRegeneronPhase 1B7-H3USP1i
GMA-729GenmabPhase 2BCL-2USP1i
SRP-1135SareptaPhase 2/3MDM2PD-L1i